deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00064259

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

A Phase I/II Study of Oblimersen in Combination With Cisplatin and Fluorouracil in Patients With Advanced Esophageal, Gastro-Esophageal Junction and Gastric Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Adenocarcinoma of the Esophagus Adenocarcinoma of the Gastroesophageal Junction Diffuse Adenocarcinoma of the Stomach Intestinal Adenocarcinoma of the Stomach Mixed Adenocarcinoma of the Stomach Recurrent Esophageal Cancer Recurrent Gastric Cancer Squamous Cell Carcinoma of the Esophagus Stage III Esophageal Cancer Stage IIIA Gastric Cancer Stage IIIB Gastric Cancer Stage IIIC Gastric Cancer Stage IV Esophageal Cancer Stage IV Gastric Cancer
Interventions cisplatin fluorouracil oblimersen sodium
Updated 8 times since 2017 Last updated: Jan 29, 2021 Started: Jun 30, 2003 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Discontinued development of G3139 (oblimersen)

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Adenocarcinoma of the Esophagus trials with similar outcome

Browse all Adenocarcinoma of the Esophagus trials

Listed as NCT00064259, this PHASE1/PHASE2 trial focuses on Adenocarcinoma of the Esophagus and Adenocarcinoma of the Gastroesophageal Junction and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshotTerminated~Mar 2021 – ~Jul 2024 · 40 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 8 months · monthly snapshotTerminated

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Mar 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  5. Jan 2021 — Mar 2021 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1_PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1_PHASE2

    First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations